Fulcrum Therapeutics reported a reduced net loss in Q1 2025 compared to the previous year, primarily due to decreased R&D and G&A expenses. The company ended the quarter with a strong cash position, extending its cash runway into at least 2027.

Fulcrum Therapeutics reported its Q4 and full year 2024 financial results. They ended the year with $241.0 million in cash, cash equivalents, and marketable securities. Patient enrollment continues to progress in the Phase 1b PIONEER trial evaluating pociredir in patients with SCD.

Fulcrum Therapeutics reported a net loss of $21.7 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $257.2 million as of September 30, 2024, and they anticipate that the cash will be sufficient to fund operating requirements into at least 2027.

Fulcrum Therapeutics reported financial results for Q2 2024, with a net income of $55.4 million primarily due to an $80.0 million upfront payment from Sanofi. The company is on track to report topline data for the Phase 3 REACH trial of losmapimod by the end of October 2024 and continues to advance its Phase 1b PIONEER trial of pociredir.

Fulcrum Therapeutics reported its Q1 2024 financial results, highlighting a collaboration agreement with Sanofi for losmapimod, progress in the Phase 3 REACH trial for FSHD, and the appointment of Patrick Horn as Chief Medical Officer. The company's cash position was $213.3 million as of March 31, 2024, with a pro forma cash position of $293.3 million including the Sanofi upfront payment.

Fulcrum Therapeutics reported collaboration revenue of $0.9 million, R&D expenses of $19.0 million, and G&A expenses of $9.9 million for Q4 2023. The company's cash, cash equivalents, and marketable securities were $236.2 million as of December 31, 2023.

Fulcrum Therapeutics reported their Q3 2023 financial results, completed enrollment in the Phase 3 REACH trial of losmapimod in FSHD, and had the clinical hold for pociredir in SCD lifted.

Fulcrum Therapeutics reported its Q2 2023 financial results, with key highlights including the closure of screening for the Phase 3 REACH trial of losmapimod and ongoing interactions with the FDA to resolve the clinical hold for FTX-6058. The company's cash position remains strong, expected to fund operations into mid-2025.

Fulcrum Therapeutics reported a net loss of $24.8 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities were $297.8 million as of March 31, 2023. They are on track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) during 2H’23 and active discussions continue with the U.S. Food and Drug Administration (FDA) to resolve clinical hold for FTX-6058 in sickle cell disease (SCD).

Fulcrum Therapeutics reported a collaboration revenue of $0.7 million and a net loss of $26.1 million for the fourth quarter of 2022. The company is working to address the clinical hold on FTX-6058 and remains on track to complete enrollment in the losmapimod Phase 3 REACH trial during 2H’23.

Fulcrum Therapeutics reported a net loss of $23.7 million for the third quarter of 2022, with collaboration revenue at $1.2 million and operating expenses totaling $25.5 million. The company's cash, cash equivalents, and marketable securities were $221.8 million as of September 30, 2022, expected to fund operations into late 2024.

Fulcrum Therapeutics reported financial results for Q2 2022, highlighted by key milestones in their clinical programs including compelling proof of concept data for 6058 and the initiation of the first registrational trial for FSHD, while also announcing a strategic plan to realign internal resources to support clinical programs and extend cash runway.

Fulcrum Therapeutics reported a net loss of $25.9 million for the first quarter of 2022. The company's clinical programs continued to progress, with upcoming milestones including data presentations for FTX-6058 and the initiation of the Phase 3 REACH trial for losmapimod.

Fulcrum Therapeutics reported collaboration revenue of $5.1 million for the fourth quarter of 2021, compared to $4.2 million for the fourth quarter of 2020. Research and development expenses were $18.9 million for the fourth quarter of 2021, as compared to $16.1 million for the fourth quarter of 2020. General and administrative expenses were $9.7 million for the fourth quarter of 2021, as compared to $5.9 million for the fourth quarter of 2020. Net loss was $23.5 million for the fourth quarter of 2021, as compared to a net loss of $17.7 million for the fourth quarter of 2020.

Fulcrum Therapeutics reported financial results for the third quarter of 2021, highlighting progress in lead programs for FSHD and sickle cell disease and the potential of FTX-6058 as a functional cure for sickle cell disease. The company raised $144.2 million in gross proceeds extending cash runway into 2024.

Fulcrum Therapeutics reported positive interim results from its Phase 1 trial for FTX-6058 in sickle cell disease and plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients in Q4 2021. The company's cash runway extends into Q1 2023.

Fulcrum Therapeutics reported a net loss of $17.0 million for the first quarter of 2021, with collaboration revenues of $4.8 million. The company's cash, cash equivalents, and marketable securities were $143.9 million as of March 31, 2021, which is expected to fund operations into the fourth quarter of 2022.

Fulcrum Therapeutics reported fourth quarter 2020 financial results, including collaboration revenue of $4.2 million and a net loss of $17.7 million. The company discontinued its Phase 3 COVID-19 trial and extended its cash runway into Q4 2022.

Fulcrum Therapeutics reported progress in their ReDUX4 trial and are on track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020. They also announced key appointments to the management team and reported a cash runway into 2Q 2022.

Fulcrum Therapeutics reported on key progress across its pipeline, including positive interim data from the ReDUX4 trial and progress with FTX-6058. The company also expanded its research efforts into genetic cardiomyopathies and initiated a Phase 3 trial for losmapimod in hospitalized patients with COVID-19. Fulcrum strengthened its cash position through a private placement.

Fulcrum Therapeutics reported a net loss of $18.5 million for the first quarter of 2020, compared to a net loss of $36.8 million for the first quarter of 2019. As of March 31, 2020, cash, cash equivalents, and marketable securities were $81.2 million.

Fulcrum Therapeutics reported a net loss of $16.1 million for the fourth quarter of 2019, compared to a net loss of $8.9 million for the fourth quarter of 2018. As of December 31, 2019, cash and cash equivalents were $96.7 million.